Axonics Announces $20.5 Million Second Closing of its Series C Financing

By Raymond Cohen on

Irvine, CA – July 6, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $20.5 million second closing of its Series C financing, bringing the total amount of capital raised for its Series C to $35 million.

The second closing of the Series C round included two new investors,

Positive Initial Results of the Axonics® RELAX-OAB Clinical Study Presented at the International Neuromodulation Society World Congress

By Raymond Cohen on

Irvine, CA, and Edinburgh, Scotland, May 31, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, today announced the presentation of positive initial results from its prospective, multicenter clinical study at the 2017 International Neuromodulation Society (INS) World Congress in Edinburgh, Scotland.

The presentation, entitled “A rechargeable sacral neuromodulation system for the treatment of overactive bladder: interim results of a prospective,

Axonics Announces $14.5 Million First Close of Series C Financing

By Raymond Cohen on

Irvine, CA – May 2, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that it has completed a $14.5 million first closing of its Series C financing.

Axonics intends to raise $30 million in its Series C financing. Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S.

Axonics to Present Results of the RELAX-OAB Clinical Study at the International Neuromodulation Society World Congress

By Raymond Cohen on

Irvine, CA, April 18, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that initial results from its prospective, multicenter clinical study will be presented for the first time at the International Neuromodulation Society (INS) World Congress on May 30, 2017 in Edinburgh, Scotland.

Professor Philip Van Kerrebroeck, MD, PhD, Chair of the Dept.

Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

By Raymond Cohen on

Irvine, CA, February 23, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics four new U.S. patents relating to its implantable sacral neuromodulation technology.

  • US 9,555,246 and US 9,561,372 relate to an integrated electromyography (EMG) technology that aids in accurate placement during the lead implantation procedure.

Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada

By Raymond Cohen on

Irvine, CA, January 5, 2017 – Axonics Modulation Technologies, Inc. announced today that it received a Homologation d’un instrument médical (medical device approval) for the first rechargeable Sacral Neuromodulation (r-SNMTM) System® to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention.

The Health Canada license confirms that the Axonics® product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada.

Axonics Announces First Fecal Incontinence Patients Implanted with its Miniaturized Rechargeable Sacral Neuromodulation System

By Raymond Cohen on

Irvine, CA, December 6, 2016 – Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal dysfunction, announced today that the first Fecal Incontinence patients were successfully implanted at the University Hospital Southampton NHS Foundation Trust in Southampton, United Kingdom.

Two patients were implanted by Thomas Dudding M.D., FRCS, Consultant, Colorectal & Pelvic Floor Surgeon.

Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology

By Raymond Cohen on

Irvine, CA, September 26, 2016 Axonics Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics a new U.S. patent relating to its implantable neuromodulation technology for the treatment of urinary and fecal dysfunction.

U.S. Patent No. 9,427,574 relates to helical anchoring devices with a plurality of tines that engage tissue to inhibit migration of an implanted lead of a neuromodulation system.

Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling

By Raymond Cohen on

European Approval Granted for 1.5T and 3T MRI Scans

 Irvine, CA, July 28, 2016 – Axonics® Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that it has received magnetic resonance imaging (MRI) conditional labeling approval in Europe for its SNM System. Patients receiving implants of the Axonics SNM System are now able to safely undergo head and neck MRI scans in 1.5 Tesla and 3 Tesla environments.

Axonics Announces First Patients Treated in Sacral Neuromodulation Study

By Raymond Cohen on

 

Post-market Clinical Study Evaluates Axonics Miniaturized, Rechargeable System for Overactive Bladder Patients

 Irvine, CA, June 20, 2016 – Axonics Modulation Technologies, Inc., developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that its first patients were successfully implanted at both the National Hospital for Neurology and Neurosurgery in London and Maastricht University Medical Centre in the Netherlands.